Gene Therapy Pharmacology: CRISPR, Viral Vectors, FDA Approvals and 2026 Safety

Evidence and references reviewed: 10 November 2026.

Gene therapy modifies gene expression or the biological properties of cells to produce a therapeutic effect. Approaches include adding genetic material, modifying a patient’s cells outside the body, and editing a genomic target. These technologies do not share one mechanism, dose unit, pharmacokinetic profile or safety profile.1

Different gene therapies have distinct mechanisms

Platform Pharmacologic mechanism Principal issue
In vivo AAV gene addition Deliver a functional transgene to selected tissues; many vector genomes remain episomal. Vector distribution, immune response, expression durability, organ toxicity and possible integration.
Ex vivo lentiviral gene addition Collected stem cells receive a genetic construct, then are reinfused after preparation. Integration-related risks, conditioning toxicity, engraftment and long-term clonal surveillance.
Ex vivo CRISPR gene editing Targeted genomic alteration of collected cells, followed by cell manufacturing and reinfusion. Editing efficiency, off-target changes, myeloablative conditioning and recovery.
CAR-T cellular immunotherapy Engineered T cells recognize antigen-bearing malignant cells. Cytokine release syndrome, neurotoxicity, infection, cytopenias and secondary T-cell malignancy risks.
Locally administered gene therapy Delivery to retina or another accessible tissue. Local tissue injury and the product’s own genetic, immune and durability risks.

The words “gene therapy” do not identify the exact mechanism. Gene addition does not necessarily edit the patient’s chromosomal sequence, while genome editing can alter DNA at a targeted locus. CAR-T products use engineered immune cells and must not be described as if they have the pharmacokinetics of a conventional small molecule. FDA indications and labeling are product-specific, and the official list of licensed products changes over time.1,11

In vivo delivery and ex vivo modification

In in vivo therapy, a vector or other delivery system is administered to reach a target tissue. In ex vivo therapy, cells are collected, modified during manufacturing and administered afterward. Viral vectors, plasmids and genetically modified cells are among the platforms described by the FDA. Gene therapy does not necessarily replace a defective gene or permanently correct every affected cell.1

Examples: product identity matters

Product Active therapy Selected indication or eligibility point
HEMGENIX Etranacogene dezaparvovec-drlb; factor IX gene transfer. Selected adults with hemophilia B, including those using factor IX prophylaxis or meeting specified serious-bleeding criteria.2
ROCTAVIAN Valoctocogene roxaparvovec-rvox; AAV-based factor VIII gene therapy. Adults with severe hemophilia A without pre-existing AAV5 antibodies detected by an approved test.3
LUXTURNA Voretigene neparvovec-rzyl. Confirmed biallelic RPE65 mutation-associated retinal dystrophy; eligibility requires specialist assessment.4
ZOLGENSMA Onasemnogene abeparvovec-xioi. Children younger than two years with spinal muscular atrophy and biallelic SMN1 mutations under its US indication.5
CASGEVY Exagamglogene autotemcel; autologous genome-edited hematopoietic stem cells. Sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta-thalassemia, subject to the current product-specific eligibility criteria.6

These regulatory examples do not establish local availability or suitability for every patient. Full eligibility assessment is more detailed than the disease name alone.2,3,4,5

New regulatory examples and why eligibility matters

Since gene therapies are indicated for specific genotypes, disease stages or clinical circumstances, a diagnosis alone cannot establish eligibility. For example, LUXTURNA is linked to confirmed biallelic RPE65-related retinal dystrophy; CASGEVY uses autologous edited hematopoietic stem cells for eligible patients with selected hemoglobinopathies; and HEMGENIX and ROCTAVIAN involve different hemophilia diseases and eligibility rules.2,3,4,6

US FDA product licensing is not identical to approval in the UK, European Union, India, Caribbean or other jurisdictions. The exact approved indication may change with safety data; review the current FDA product page and prescribing information rather than relying on a static list of “all approved gene therapies.”11

CRISPR editing differs from viral gene addition

CASGEVY uses CRISPR/Cas9 editing of the erythroid-specific BCL11A enhancer in collected CD34+ cells to increase fetal hemoglobin. Editing components are delivered by electroporation, not lentiviral gene addition. Treatment requires cell collection, manufacturing, myeloablative conditioning and infusion. Engraftment and blood counts require specialist follow-up.6

Why ex vivo gene editing involves more than a single infusion

CASGEVY uses the CRISPR/Cas9 system to edit the erythroid-specific enhancer of BCL11A in collected hematopoietic stem and progenitor cells. The intended biological effect is increased fetal hemoglobin (HbF) production after marrow engraftment, reducing sickling-related complications in selected patients. It is not viral transfer of a normal adult beta-globin gene.6

Clinical treatment requires stem-cell collection, specialized manufacturing, preinfusion conditioning (commonly myeloablation), infusion, recovery and long-term monitoring. Complications may arise from the conditioning regimen or underlying disease as well as the edited cells. Durable benefit does not mean the patient avoids all future follow-up, reproductive counseling or surveillance for organ complications.

Pharmacology beyond plasma half-life

Relevant questions include the distribution of genetic material or modified cells, persistence of expression, and durability of the biological effect. Assigning a single half-life or universal renal elimination pathway to all gene therapies is misleading. Long-term observation is tailored to the platform and potential delayed effects.7

Dose units also differ: ROCTAVIAN uses vector genomes per kilogram, whereas CASGEVY uses CD34+ cells per kilogram. These units cannot be interchanged, and preparation and administration follow product-specific instructions.3,6

Gene-therapy pharmacokinetics are different from ordinary drugs

A standard medicine may be described by plasma Cmax, distribution volume, clearance and elimination half-life. Gene therapy needs additional parameters, including vector genome dose, biodistribution, shedding, cellular persistence, transgene expression, immune response and long-term biological effect. Different products may be dosed in vector genomes/kg, transducing units or viable cells/kg; numerical doses should never be converted across platforms as if these units measured the same exposure.7

For AAV-based therapy, preexisting antibodies may reduce transduction and influence eligibility; some products require specific capsid-antibody testing. Liver enzymes, platelet counts, immunity and concomitant medicines may require monitoring. For hematopoietic cell products, engraftment, blood counts, infections, reproductive toxicity from conditioning and potential clonal changes are prominent concerns.

Safety and surveillance

Vector-related malignancy risk must not be described as zero. On 6 November 2026, the FDA reported an investigation of malignancies after ZOLGENSMA, including cases with evidence of AAV-vector integration involving the GLI1 oncogene. This is an ongoing assessment, not a quantified universal cancer risk for every gene therapy. Patients and clinicians should follow current product information and safety updates.8

Modified immune-cell therapies have distinct warnings. The FDA required boxed warnings for T-cell malignancies following specified BCMA-directed or CD19-directed autologous CAR-T therapies and recommends lifelong monitoring for new malignancies. This warning should not be indiscriminately assigned to all gene-transfer and gene-editing products.9

Conditioning and recovery carry additional risks. CASGEVY warnings include engraftment failure, delayed platelet recovery, hypersensitivity and off-target editing concerns. A one-time infusion does not mean a one-visit treatment course.6

November 2026 FDA signal: insertional oncogenesis after Zolgensma

On 6 November 2026, the FDA announced postmarketing reports of tumors after ZOLGENSMA, including three cases associated with the GLI1 oncogene. In two cases, molecular analyses found AAV vector DNA integrated in or near the GLI1 regulatory region, providing evidence consistent with product-related insertional oncogenesis. Other observed tumors included nervous-system, spinal/paraspinal and renal neoplasms. The absolute incidence and patient-level predictors remain uncertain; the regulator is investigating, not claiming every AAV infusion inevitably causes cancer.8

The FDA determined that potential malignancy risk also applies to ITVISMA, which uses the same vector/construct but a different administration route and age indication; at the time of the alert, no neoplasia cases had been reported after ITVISMA. FDA stated that the overall benefit–risk balance of the two products remained favorable for their approved indications, while recommending vigilance and long-term follow-up.8

Elevidys: an example of a safety-driven indication change

In November 2025, FDA approved a boxed warning for acute serious liver injury and acute liver failure for the Duchenne muscular dystrophy AAV therapy ELEVIDYS (delandistrogene moxeparvovec-rokl), following reports of fatal liver failure. Its U.S. indication was restricted to ambulatory patients aged four years or older with a confirmed DMD mutation; it is no longer approved for nonambulatory patients under that indication. The current label includes specialist assessment, steroid cover and liver monitoring.10

These two alerts illustrate different potential mechanisms: AAV integration-associated oncogenesis and acute hepatotoxicity. They must not be conflated or applied as identical boxed warnings to all vectors, CRISPR products and CAR-T therapies.

Interpreting benefit responsibly

Durable benefit is possible, but permanent cure should not be promised. Compare treatment with the available alternatives for the specific disease, considering eligibility, uncertainty, burden and follow-up. FDA guidance emphasizes risk-based long-term surveillance because delayed adverse effects can emerge after an initial response.7

Practical monitoring and consent checklist

Before treatment After treatment
Confirm genotype, approved indication and disease severity; review alternative treatments and the expected outcome. Assess clinical response and durability with disease-specific functional and laboratory measures.
Review vector immunity, liver function, infection and organ-specific risks where relevant. Monitor organ toxicity, infection, blood counts and immune complications as directed by the label.
Plan cell collection, conditioning, hospital stay and fertility counseling for ex vivo approaches. Observe engraftment, late malignancy signals and reproductive/organ effects when relevant.
Explain known benefits, uncertainty and the need for long-term follow-up. Report suspected adverse effects and maintain an up-to-date product-specific surveillance plan.

The FDA’s long-term follow-up guidance is risk-based, not a universal fixed follow-up duration for every product. Some vector or integrating platforms require observation for many years, and patients must receive product-specific instructions.7

Frequently asked questions

Does gene therapy always edit the patient’s DNA?

No. Gene addition, gene editing and engineered cell therapies have different mechanisms.

Is every gene therapy a permanent cure?

No. Durability depends on cell type, vector, expression, engraftment, immune response and disease biology.

Why is Zolgensma being investigated in November 2026?

FDA reported tumors associated with AAV integration and the GLI1 oncogene; the risk is under active investigation.8

Was Elevidys’ approved population changed?

Yes. FDA restricted the indication to ambulatory patients aged four or more with a confirmed DMD mutation and added major liver safety warnings.10

Why do some gene-edited cells require chemotherapy-like conditioning?

Conditioning creates marrow space for modified hematopoietic stem-cell engraftment; it adds its own toxicity and monitoring needs.

References

  1. US Food and Drug Administration. What is gene therapy? [Internet] [cited 2026 Nov 10]. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy
  2. US Food and Drug Administration. HEMGENIX: product information [Internet] [cited 2026 Nov 10]. Available from: https://www.fda.gov/vaccines-blood-biologics/vaccines/hemgenix
  3. BioMarin Pharmaceutical Inc. ROCTAVIAN (valoctocogene roxaparvovec-rvox): prescribing information [Internet] [cited 2026 Nov 10]. Available from: https://www.fda.gov/media/169937/download
  4. US Food and Drug Administration. LUXTURNA: product information [Internet] [cited 2026 Nov 10]. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/luxturna
  5. US Food and Drug Administration. ZOLGENSMA: product information [Internet] [cited 2026 Nov 10]. Available from: https://www.fda.gov/vaccines-blood-biologics/zolgensma
  6. National Library of Medicine. CASGEVY (exagamglogene autotemcel): prescribing information. DailyMed [Internet] [cited 2026 Nov 10]. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7c3e12ad-e2fe-4d3f-a630-ea7364d9e846&type=display
  7. US Food and Drug Administration. Long term follow-up after administration of human gene therapy products: guidance for industry. 2020 [Internet] [cited 2026 Nov 10]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/long-term-follow-after-administration-human-gene-therapy-products
  8. US Food and Drug Administration. FDA investigating serious risk of malignancy linked to Zolgensma gene therapy. 2026 Nov 6 [Internet] [cited 2026 Nov 10]. Available from: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-malignancy-linked-zolgensma-gene-therapy
  9. US Food and Drug Administration. FDA requires boxed warning for T cell malignancies following treatment with BCMA-directed or CD19-directed autologous CAR T cell immunotherapies. 2024 Apr 18 [Internet] [cited 2026 Nov 10]. Available from: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed
  10. US Food and Drug Administration. FDA approves new safety warning and revised indication that limits use for Elevidys following reports of fatal liver injury [Internet]. 14 Nov 2025. Available from: FDA announcement [cited 2026 Nov 10].
  11. US Food and Drug Administration. Approved cellular and gene therapy products [Internet]. Available from: FDA product list [cited 2026 Nov 10].

⚠️ Medical Disclaimer

This article is intended for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this article.

The information provided here is based on current scientific literature and established pharmacological principles. However, medical knowledge evolves continuously, and individual patient responses to medications may vary. Healthcare professionals should always use their clinical judgment when applying this information to patient care.

Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *